Retatrutide vs Cagrilintide
Retatrutide and cagrilintide are the two newest compounds in the metabolic research peptide category, and both are still in late-stage clinical development rather than approved medicines. That is where the similarity ends. Retatrutide is a triple incretin-and-glucagon receptor agonist; cagrilintide is an amylin analogue. This page compares them as research compounds for Philippine laboratories deciding which to stock. For laboratory and research use only.
Side by side
| Retatrutide | Cagrilintide | |
|---|---|---|
| Family | Incretin/glucagon analogue (GIP-based) | Amylin analogue |
| Receptors studied | GIP, GLP-1 and glucagon receptors | Amylin receptors and calcitonin receptor |
| Development code | LY3437943 (Eli Lilly) | NNC0174-0833 (Novo Nordisk) |
| Clinical stage, 2026 | Phase 3 ongoing | Phase 3 ongoing (largely in combination programs) |
| Reported half-life in the literature | Approximately 6 days | Approximately 7 to 8 days |
| Regenwell vial sizes | 10 mg, 20 mg, 30 mg | 5 mg |
| Regenwell price from | ₱1,995 (10 mg, Vial + BAC Water) | ₱2,352 (5 mg, Vial + BAC Water) |
Three receptors versus one hormone system
Retatrutide is the broadest single compound in this category: it is engineered to engage the GIP receptor, the GLP-1 receptor and the glucagon receptor from one molecule. Cagrilintide is narrow by design: it is a stabilised amylin, acting on the amylin receptor family, and does not touch the incretin or glucagon receptors at all. A laboratory that wants to study several pathways with one compound reaches for retatrutide. A laboratory that wants to add the amylin pathway to an existing incretin model reaches for cagrilintide.
Where the literature stands
Both compounds have published phase 2 data and ongoing phase 3 programs as of 2026. Retatrutide's literature is centred on the compound itself. Cagrilintide's literature is dominated by combination studies with a GLP-1-class partner, and stand-alone cagrilintide papers are fewer. For a researcher, that means retatrutide reference data is easier to use on its own, while cagrilintide reference data usually needs to be read in the context of a combination design.
Practical differences at the bench
- Vial content. Retatrutide starts at 10 mg per vial, cagrilintide at 5 mg. Plan concentration calculations with the concentration reference.
- Cost per milligram. Retatrutide 10 mg is about ₱200/mg; cagrilintide 5 mg is about ₱470/mg. Ten-vial Kits (₱13,750 and ₱16,300 respectively) reduce both and ship free.
- Solubility and handling. Both are lipidated peptides and reconstitute in bacteriostatic water. Both are stored cool, dry and dark as powders, frozen at -20°C for long storage, and refrigerated at 2 to 8°C once reconstituted.
- Certificates. Batch certificate status for both is on the lab testing page.
Which to order
Order retatrutide for a multi-receptor incretin/glucagon study. Order cagrilintide for an amylin-pathway study, or to add to a tirzepatide or retatrutide model. Laboratories running combination models most often pair cagrilintide with tirzepatide, because tirzepatide has the deeper reference literature; see Tirzepatide vs Cagrilintide.
Ordering in the Philippines
- Retatrutide: 10, 20, 30 mg; Vial + BAC Water, Complete Set or Kit.
- Cagrilintide: 5 mg; Vial + BAC Water, Complete Set or Kit.
Nationwide tracked delivery, GCash, Maya, cards and bank transfer, free shipping over ₱10,000. Sourcing checks: six-point checklist.
Related: Tirzepatide vs Retatrutide, all three compared, compare hub.
All products and information on this page are intended strictly for laboratory and research use only. They are not for human or animal use and are not intended to diagnose, treat, cure or prevent any condition. Nothing here is medical advice.